Zimmer Biomet (NYSE:ZBH) received a $140.00 price target from stock analysts at Cowen in a research note issued on Friday, TipRanks reports. The firm presently has a “hold” rating on the medical equipment provider’s stock. Cowen’s target price would indicate a potential upside of 4.09% from the company’s current price.

Several other brokerages also recently issued reports on ZBH. Sanford C. Bernstein upgraded shares of Zimmer Biomet from an “underperform” rating to a “market perform” rating and set a $121.71 price target on the stock in a research report on Tuesday, June 11th. Needham & Company LLC upped their price target on shares of CoStar Group from $500.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Barclays upped their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research report on Monday, April 15th. ValuEngine upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Cantor Fitzgerald set a $135.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, April 26th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $131.81.

NYSE ZBH traded up $10.59 on Friday, hitting $134.50. 5,793,693 shares of the company were exchanged, compared to its average volume of 1,031,763. The firm’s 50 day simple moving average is $120.04. The company has a market cap of $27.55 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.51 and a beta of 1.14. The company has a current ratio of 2.00, a quick ratio of 0.97 and a debt-to-equity ratio of 0.72. Zimmer Biomet has a 1-year low of $96.99 and a 1-year high of $136.22.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.92 EPS. On average, analysts expect that Zimmer Biomet will post 7.81 EPS for the current fiscal year.

In other Zimmer Biomet news, insider Sang Yi sold 426 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $114.88, for a total transaction of $48,938.88. Following the transaction, the insider now directly owns 1,457 shares in the company, valued at approximately $167,380.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.72% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Sound View Wealth Advisors LLC increased its stake in shares of Zimmer Biomet by 2.0% in the 1st quarter. Sound View Wealth Advisors LLC now owns 4,456 shares of the medical equipment provider’s stock valued at $569,000 after acquiring an additional 87 shares during the last quarter. Advisory Services Network LLC increased its stake in Zimmer Biomet by 2.7% during the 4th quarter. Advisory Services Network LLC now owns 3,552 shares of the medical equipment provider’s stock worth $369,000 after purchasing an additional 94 shares in the last quarter. MML Investors Services LLC increased its stake in Zimmer Biomet by 3.4% during the 4th quarter. MML Investors Services LLC now owns 2,912 shares of the medical equipment provider’s stock worth $302,000 after purchasing an additional 96 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in Zimmer Biomet by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 10,800 shares of the medical equipment provider’s stock worth $1,379,000 after purchasing an additional 100 shares in the last quarter. Finally, Motco increased its stake in Zimmer Biomet by 86.2% during the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 100 shares in the last quarter. 88.69% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: Stock Split

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.